Blog | HemaCare

Nancy Andon, MSc


Recent Posts

HemaCare Publication Highlights Role of Cell Therapy Starting Materials

Jan 7, 2020 10:04:00 AM / by Nancy Andon, MSc posted in Gene Therapy, Cell Therapy

0 Comments

HemaCare Corporation’s latest publication in BioPharm International [1] sheds light on a topic that has been preoccupying some of the best minds in cell therapy research; the need to ensure a reliable supply of top-notch starting materials for up-and-coming cell and gene therapies.

Unlike traditional medical treatments, the raw materials for these therapies cannot simply be manufactured. Instead, the supply of starting materials relies on a steady influx of voluntary donors willing to take the time to undertake a fairly complex screening process and donate peripheral blood or bone marrow for altruistic reasons. Nor is a reliable donor pool the only criteria necessary to supplying materials for a successful cellular therapeutic. Starting material quality and consistency ultimately determine the reliable efficacy of the final product.

Read More

Happy New Year! The Top Ten HemaCare Blogs of 2019

Dec 19, 2019 10:11:00 AM / by Nancy Andon, MSc posted in Cell Therapy

0 Comments

It’s hard to believe that 2020 is almost here! As 2019 draws to a close, it’s a good time to look back on a year abundant in innovative medical discoveries and advances. To highlight some of the most interesting developments in the cell therapy field, we are pleased to present HemaCare’s 10 most popular blogs of the year, and the improvements in healthcare that they represent. Enjoy the countdown!

Read More

CAR T Cell Drug Touts Long-Term Survival Rates

Dec 17, 2019 10:00:00 AM / by Nancy Andon, MSc posted in CAR-T, Cell Therapy, T Cells

0 Comments

CAR T cell therapy has been one of the most exciting medical advances of this decade. As a type of immunotherapy, CAR T treatment consists of collecting patient-derived immune T cells, and genetically engineering them to recognize and fight invasive cancer cells. The first of these therapies to receive U.S. Food and Drug Administration (FDA) approval, Novartis’ Kymriah®, and Gilead’s Yescarta® garnered international attention for their astonishing success rates in clinical trial.

Read More

HemaCare Publication Shines Spotlight on Healthy Donors

Dec 10, 2019 10:02:00 AM / by Nancy Andon, MSc posted in Cell Therapy, Cell Therapy Manufacturing

0 Comments

HemaCare is pleased to announce the publication of their latest article [1] in the current issue of BioProcess International.

The piece, entitled “The Cell Therapy Industry Needs High-Quality Healthy-Donor Material”, gives readers expert insight into the growing demand for cell therapy starting material, and how that demand is impacting suppliers.

Read More

HemaCare Healthy Donor Cells Aid New CAR T Cell Design

Nov 19, 2019 10:00:00 AM / by Nancy Andon, MSc posted in CAR-T, PBMCs, T Cells

0 Comments

A collaborative research effort on the part of 3 top-tier pharmaceutical companies cite using HemaCare sourced healthy donor PBMCs for their work on developing an allogeneic CAR T cell therapy. [1] CAR T therapies are among the most promising new cancer treatments approved by the FDA. These therapies have had remarkable success rates in people suffering from aggressive leukemia and lymphoma, who would otherwise be left without treatment options. The number of people who can be treated with this type of therapy is limited, however. CAR T treatment is an autologous therapy, relying on collecting and modifying a patient’s own T cells to fight their disease. Since cancer patients often suffer from a compromised immune system, it’s quite difficult to collect enough healthy T cells for treatment. Several research groups have been looking for a way to make an allogeneic CAR T cell treatment, in which T cells can be sourced from healthy donors.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts